Anteris Technologies Ltd. (AU:AVR) has released an update.
Anteris Technologies Ltd. reports a successful quarter with advancements in their DurAVR™ valve technology, evidencing significant haemodynamic improvements in patients and moving closer to U.S. commercialization with the commencement of a pivotal trial. The company remains financially robust with a cash balance of $10.6 million, while strategically investing in R&D and exploring potential business partnerships and a dual listing on NASDAQ and ASX. As the company progresses, it keeps a keen eye on strategic partnerships and investment opportunities to further its reach in the structural heart disease market.
For further insights into AU:AVR stock, check out TipRanks’ Stock Analysis page.
